TrialCancer medicine2024

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.

Jieran Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.